Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

A number of other analysts have also commented on ABEO. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th.

Abeona Therapeutics Stock Down 1.2 %

ABEO stock opened at $5.93 on Friday. The firm has a market cap of $257.78 million, a PE ratio of -2.20 and a beta of 1.43. The business has a 50 day moving average of $5.66 and a 200 day moving average of $5.77. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $9.01. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Abeona Therapeutics during the third quarter valued at $84,000. Charles Schwab Investment Management Inc. bought a new stake in Abeona Therapeutics during the third quarter valued at about $151,000. XTX Topco Ltd bought a new stake in Abeona Therapeutics during the third quarter valued at about $160,000. JPMorgan Chase & Co. raised its holdings in Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 28,606 shares during the period. Finally, Trexquant Investment LP bought a new stake in Abeona Therapeutics during the fourth quarter valued at about $382,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.